Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 14499173

Decrease of B-cells and autoantibodies after low-dose methotrexate.

Ingrid Böhm
View original source ↗Export metadata ↓

Abstract

The purpose was to assess the efficacy of low-dose methotrexate (MTX) on immunological parameters in patients with lupus erythematosus (LE) under short- (</=10 weeks) vs. long-term (>10 weeks) conditions. Patients who did not respond to classical LE treatment (antimalarials and/or glucocorticosteroids) were retrospectively analyzed. Twenty-two LE-patients received 10-30 mg MTX per week. Sera and ethylenediaminetetra-acetic blood specimens were analyzed for autoantibodies and lymphocyte subsets (flow cytometry), respectively. Clinical improvement occurred in 21 patients (complete response n = 15, 68.2%). B-cells were the main targets: their absolute number significantly dropped down after long-term treatment (290 +/- 49 vs. 221 +/- 41 microl(-1), P = 0.00254). This was accompanied by down-regulation of autoantibodies. The effect on B-cells was more pronounced in patients with (before vs. long-term 172 +/- 34 vs. 99 +/- 15 microl(-1), P = 0.02853) than without autoantibodies (169 +/- 40 vs. 144 +/- 51 microl(-1), P = 0.55406). MTX did not induce immunosuppression. Low-dose MTX has different short- and long-term effects on immunologic parameters, which could explain the clinical improvement.

Explore related subjects

Adjuvants, ImmunologicAdultAgedAutoantibodiesB-LymphocytesFemaleFollow-Up StudiesHumansLupus Erythematosus, CutaneousLupus Erythematosus, SystemicLymphocyte CountLymphocyte SubsetsMaleMethotrexateMiddle AgedRetrospective StudiesTreatment OutcomeJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ingrid Böhm. 2003. Decrease of B-cells and autoantibodies after low-dose methotrexate.. https://doi.org/10.1016/s0753-3322(03)00086-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism.

BACKGROUND: Melatonin, the main secretory product of the pineal gland, inhibits the growth of several types of cancer cells. Melatonin limits human prostate cancer cell growth by a mechanism which involves the regulation of androgen receptor function but it is not clear whether other mechanisms may also be involved. METHODS: Time-course and dose-dependent studies were performed using androgen-dependent (LNCaP) and independent (PC3) prostate cancer cells. Cell number, cell viability, and cell cycle progression were studied. Neuroendocrine differentiation of these cells was evaluated by studying morphological and biochemical markers. Finally, molecular mechanisms including the participation of melatonin membrane receptors, intracellular cAMP levels, and the PKA signal transduction pathway were also analyzed. RESULTS: Melatonin treatment dramatically reduced the number of prostate cancer cells and stopped cell cycle progression in both LNCaP and PC3 cells. In addition, it induced cellular differentiation as indicated by obvious morphological changes and neuroendocrine biochemical parameters. The role of melatonin in cellular proliferation and differentiation of prostate cancer cells is not mediated by its membrane receptors nor related to PKA activation. CONCLUSIONS: The treatment of prostate cancer cells with pharmacological concentrations of melatonin influences not only androgen-sensitive but also androgen-insensitive epithelial prostate cancer cells. Cell differentiation promoted by melatonin is not mediated by PKA activation although it increases, in a transitory manner, intracellular cAMP levels. Melatonin markedly influences the proliferative status of prostate cancer cells. These effects should be evaluated thoroughly since melatonin levels are diminished in aged individuals when prostate cancer typically occurs.

Adjuvants, Immunologic↗
PubMed2005

Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.

BACKGROUND: Prostate cancer is the most common malignancy in Swedish and American men. Effective curative treatment modalities are debilitating and available only for localized disease. As an immunotherapy approach, DNA encoding prostate-specific antigen (PSA), was used to immunize mice and induce PSA-specific cellular immunity. METHODS: A plasmid expressing PSA, alone or in combination with plasmids coding for GM-CSF and/or IL-2, was used for DNA immunization. Cr-release, intracellular IFN-gamma cytokine staining, and tumor challenge assays were used to evaluate the immune response. RESULTS: The DNA vaccine induces PSA-specific cytotoxic T lymphocytes (CTLs) and when co-injected with IL-2 and GM-CSF it protects four of five mice against a PSA-expressing tumor challenge. CONCLUSIONS: We demonstrate that immunization with a PSA DNA vaccine can evoke PSA-specific cellular immune responses. We also show, for the first time, that a PSA DNA vaccine can induce anti-tumor immunity in vivo.

Adjuvants, Immunologic↗
PubMed2004

Enhancement of the immunogenicity of DNA vaccine against infectious bursal disease virus by co-delivery with plasmid encoding chicken interleukin 2.

The immunoregulatory activity of a nonmammalian interleukin 2 (IL-2), chicken IL-2 (chIL-2), was investigated using a DNA vaccine against infectious bursal disease virus (IBDV) as a model. Coadministration of a plasmid encoding the VP2 gene of IBDV (pCI-VP2) and a plasmid encoding chicken IL-2 gene (pCI-chIL-2) enhances bursal protection against both the homologous IBDV strain ZJ2000 and the heterologous strain BC6/85 compared to administration of pCI-VP2 alone. Vaccination with pCI-VP2 alone induces low bursal protection against ZJ2000 and only protects chickens from clinical outbreaks and mortality, but not from bursal damage caused by BC6/85. Co-administration of the plasmid encoding the polyprotein gene of IBDV (pCI-VP2/4/3) and pCI-chIL-2 provides complete protection (15/15) against ZJ2000 and satisfactory protection (13/15) against BC6/85. In contrast, only 10 out of 15 chickens and 6 out of 15 chickens were protected against ZJ2000 and BC6/85, respectively, using the pCI-VP2/4/3 vaccination alone. A significant increase in the IBDV-specific neutralizing antibody response was also observed in chickens that received pCI-VP2/4/3 plus pCI-chIL-2 as compared with those that received the pCI-VP2/4/3 vaccination alone. By administrating different amounts of plasmid DNA, we confirmed that the pCI-chIL-2, but not the backbone plasmid pCI, contributes to increased immunoprotection of DNA vaccine against IBDV. These results strongly indicate that the efficacy of avian DNA vaccine can be modulated by co-administration of a plasmid encoding chIL-2.

Adjuvants, Immunologic↗